Progenitor Cell Therapy to Protect Stem Cells with Golden Hour Technology
News Dec 08, 2006
Progenitor Cell Therapy (PCT) and Minnesota Thermal Science (MTS) have announced a partnership agreement to incorporate Golden Hour Technology thermal packaging into PCT's national distribution system of umbilical cord blood, stem cells and other temperature sensitive cellular therapy products.
The agreement follows a rigorous validation study which shows the new Golden Hour Platelet Shipper is able to maintain the FDA-required temperature range of 20 to 24 degrees Celsius for two days in both summer and winter conditions.
PCT will offer the new container to its customers as part of its integrated quality service solutions.
Robert Preti, president and chief scientific officer for PCT, said the industry has a clear need for better temperature sensitive packaging.
"We have long known that as new cellular therapies become more available to medical and research practitioners it would become increasingly important to create a state of the art transportation system. The Golden Hour shipping containers are a key component, offering a significant improvement in efficacy."
According to MTS president George Flora the agreement sets the stage for broader adoption of Golden Hour Technology in the biotech industry.
"The medical use of stem cells is growing exponentially. Progenitor Cell Therapy is the perfect partner for us due to the importance they have placed on solving the logistical challenges of cell therapy commercialization. Their planning begins at the point of collection and carries through to the end user, an approach they believe is crucial to maintaining quality control."
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019